A Phase I Study of G3139 Subcutaneous in Solid Tumors

Exclusion Criteria

• •Significant medical diesese
• •History of leptomeningeal disease
• •Coexisting condition that would require the subject to continue therapy during the treatment phase of the study with a drug known to alter renal function.
• •Use of any investigational drug within 3 weeks prior to starting study medication
• •Known hypersensitivity to phosphorothioate-containing oligonucleotides
• •Pregnancy/Lactation